No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis

Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis

(2017) Nicola Veronese et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis

(2016) Guido Kranenburg et al.   ATHEROSCLEROSIS

Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial

(2016) Mohit Bhandari et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension

(2016) Jung-Min Koh et al.   YONSEI MEDICAL JOURNAL

A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial

(2015) Bente L. Langdahl et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis

(2015) Dae Hyun Kim et al.   PLoS One

Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates

(2014) Abhishek Sharma et al.   AMERICAN JOURNAL OF CARDIOLOGY

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women

(2014) Markus R. John et al.   BONE

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

(2014) T. Sugimoto et al.   OSTEOPOROSIS INTERNATIONAL

Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis

(2013) Takuo Fujita et al.   CALCIFIED TISSUE INTERNATIONAL

Risk of Serious Atrial Fibrillation and Stroke With Use of Bisphosphonates

(2013) Abhishek Sharma et al.   CHEST

RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

(2013) Elizabeth J Samelson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis

(2012) K. Henriksen et al.   BONE

Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk

(2012) Toshitaka Nakamura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis

(2011) T. Nakamura et al.   OSTEOPOROSIS INTERNATIONAL

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

(2010) Akimitsu Miyauchi et al.   BONE

Estrogen Inhibits Vascular Calcification via Vascular RANKL System

(2010) Mariana Kiomy Osako et al.   CIRCULATION RESEARCH

Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography

(2010) S. Pilz et al.   EUROPEAN HEART JOURNAL

Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis

(2010) Mark J. Bolland et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Is Withholding Osteoporosis Medication After Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death

(2010) Jeffrey R. Curtis et al.   Journal of the American Medical Directors Association

Oral bisphosphonates are associated with reduced mortality after hip fracture

(2010) L. A. Beaupre et al.   OSTEOPOROSIS INTERNATIONAL

Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study

(2010) P. N. Sambrook et al.   OSTEOPOROSIS INTERNATIONAL

Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community

(2009) Emil Hagström et al.   CIRCULATION

Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women

(2009) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study

(2008) Akimitsu Miyauchi et al.   JOURNAL OF BONE AND MINERAL METABOLISM